Episodic Migraine Clinical Trial
Official title:
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety of Atogepant in Pediatric Subjects 6 to 17 Years of Age With Episodic Migraine
Verified date | February 2024 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for participants less than 18 years of age. The main goal of the study is to evaluate the long-term safety and tolerability of atogepant in pediatric participants between the ages of 6 and 17 with episodic migraine. Atogepant is a medicine currently approved to treat adults with episodic migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of episodic migraine. This is a Phase 3, open-label study of atogepant in participants with a history of episodic migraine. Participants must have completed participation in another study of atogepant (lead-in study) or completed the screening period of that study. Participants must have 4 to 14 migraine days and less than 15 headache days in the 4-week screening electronic diary (eDiary; similar to a smart phone). Around 250 participants will be enrolled in the study at approximately 100 sites worldwide. Atogepant is a tablet taken once a day by mouth. Participants between the ages of 12 and 17 will receive high dose atogepant for 52 Weeks. Participants between the ages of 6 and 11 will receive an atogepant dose determined in the lead-in study for 52 Weeks. There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.
Status | Enrolling by invitation |
Enrollment | 250 |
Est. completion date | November 16, 2029 |
Est. primary completion date | November 16, 2029 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 17 Years |
Eligibility | Inclusion Criteria: - Participants must be between 6 and 17 years of age (inclusive), with a history of episodic migraine. - The participant must have completed the lead-in Study M21-201, the pharmacokinetic (PK) substudy in Study M21-201, or completed the 4-week screening/baseline period and screen failed due to not meeting the number of migraine day requirements for the inclusion criteria in Study M21-201, and, in the judgment of the investigator, the participant is an appropriate candidate to be treated with a daily preventive migraine treatment with atogepant (not applicable for de novo migraine participants) - Weight is >= 20 kg (44 lbs) and < 135 kg (298 lbs). - A history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3; 2018) for at least 6 months. Exclusion Criteria: - History of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine as defined by ICHD-3 (2018). - Have a current diagnosis of chronic migraine as defined by ICHD-3 (2018). - Have a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (e.g., cluster headache), or painful cranial neuropathy as defined by ICHD-3 (2018). - Have any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular, or neurologic disease. |
Country | Name | City | State |
---|---|---|---|
Canada | Montreal Children's Hospital /ID# 250649 | Montreal | Quebec |
Denmark | Aalborg Universitetshospital /Id# 247429 | Aalborg | Nordjylland |
Denmark | Regionshospitalet Godstrup /ID# 247903 | Herning | Midtjylland |
Hungary | Mind Klinika Kft. /ID# 251597 | Budapest | |
Hungary | Semmelweis Egyetem /ID# 251593 | Budapest | |
Israel | Shamir Medical Center (Assaf Harofeh) /ID# 256858 | Be'er Yaakov | HaMerkaz |
Israel | Hillel Yaffe Medical Center /ID# 248923 | Hadera | H_efa |
Italy | Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 249182 | Milan | |
Italy | Azienda Ospedaliera Universitaria Paolo Giaccone /ID# 249184 | Palermo | |
Japan | Konan Medical Center /ID# 254458 | Kobe-shi | Hyogo |
Japan | Umenotsuji Clinic /ID# 254454 | Kochi-shi | Kochi |
Japan | Tatsuoka Neurology Clinic /ID# 254456 | Kyoto | |
Japan | Yamaguchi Clinic /ID# 254763 | Nishinomiya-shi | Hyogo |
Japan | Tominaga Clinic /ID# 254451 | Osaka-shi | Osaka |
Japan | Sendai Headache and Neurology Clinic Medical Corporation /ID# 254212 | Sendai-shi | Miyagi |
Japan | Tokyo Medical University Hospital /ID# 254460 | Shinjuku-ku | Tokyo |
Poland | Athleticomed Sp. z o.o /ID# 250620 | Bydgoszcz | |
Poland | Specjalistyczne Gabinety Sp. z o.o. /ID# 250625 | Krakow | Malopolskie |
Poland | Indywidualna Praktyka Lekarska dr hab. med. Anna Szczepanska-Szerej /ID# 250622 | Lublin | Lubelskie |
Poland | Clinical Research Center Sp. z.o.o. Medic-R sp. k /ID# 250623 | Poznan | Wielkopolskie |
Poland | OHA-MED sp. z o.o /ID# 250621 | Warszawa | Mazowieckie |
Poland | MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak /ID# 250624 | Wroclaw | |
Puerto Rico | Puerto Rico Health Institute /ID# 250949 | Dorado | |
Puerto Rico | Caribbean Medical Research Center /ID# 253156 | San Juan | |
Spain | Hospital Universitario Vall d'Hebron /ID# 248457 | Barcelona | |
Spain | Hospital Clinico Universitario San Carlos /ID# 249268 | Madrid | |
Spain | Hospital Universitario Virgen del Rocio /ID# 248633 | Sevilla | |
Spain | Hospital Universitario y Politecnico La Fe /ID# 248459 | Valencia | |
Sweden | Vastra Gotealandsregionen Regionhalsan /ID# 248981 | Molnlycke | |
United Kingdom | NHS Grampian /ID# 251474 | Aberdeen | |
United States | Dent Neurosciences Research Center, Inc. /ID# 250915 | Amherst | New York |
United States | Advanced Research Center /ID# 251616 | Anaheim | California |
United States | Michigan Headache & Neurological Institute (MHNI) /ID# 250920 | Ann Arbor | Michigan |
United States | FutureSearch Trials of Neurology /ID# 251613 | Austin | Texas |
United States | Pantheon Clinical Research /ID# 251615 | Bountiful | Utah |
United States | Coastal Georgia Child Neurology /ID# 250938 | Brunswick | Georgia |
United States | Patient Priority Clinical Sites, LLC /ID# 250922 | Cincinnati | Ohio |
United States | 3A Research - East El Paso /ID# 250909 | El Paso | Texas |
United States | Core Clinical Research /ID# 250932 | Everett | Washington |
United States | Advanced Neurosciences Research, LLC /ID# 250925 | Fort Collins | Colorado |
United States | Office of Maria Ona /ID# 250939 | Franklin | Virginia |
United States | Earle Research /ID# 250908 | Friendswood | Texas |
United States | Headache Wellness Center /ID# 251612 | Greensboro | North Carolina |
United States | Northwest Florida Clinical Research Group, LLC /ID# 251614 | Gulf Breeze | Florida |
United States | Advanced Research Institute of Miami /ID# 250916 | Homestead | Florida |
United States | Rehabilitation & Neurological Services /ID# 250910 | Huntsville | Alabama |
United States | Sunwise Clinical Research /ID# 250913 | Lafayette | California |
United States | Preferred Research Partners /ID# 250937 | Little Rock | Arkansas |
United States | Alliance for Research - Long Beach /ID# 250911 | Long Beach | California |
United States | My Preferred Research LLC /ID# 250931 | Miami | Florida |
United States | Goryeb Children's Hospital /ID# 250934 | Morristown | New Jersey |
United States | Access Clinical Trials, Inc. /ID# 250914 | Nashville | Tennessee |
United States | Deaconess Clinic - Gateway Health Center /ID# 250923 | Newburgh | Indiana |
United States | Excell Research, Inc /ID# 251611 | Oceanside | California |
United States | Lynn Health Science Institute (LHSI) /ID# 250926 | Oklahoma City | Oklahoma |
United States | College Park Family Care Center Overland Park /ID# 251609 | Overland Park | Kansas |
United States | Cognitive Clinical Trials (CCT) - Papillion /ID# 251610 | Papillion | Nebraska |
United States | Proven Endpoints LLC /ID# 258083 | Ridgeland | Mississippi |
United States | Highland Clinical Research /ID# 250924 | Salt Lake City | Utah |
United States | Lumos Clinical Research Center /ID# 251608 | San Jose | California |
United States | Asclepes Research Centers - Spring Hill /ID# 250912 | Spring Hill | Florida |
United States | Family Psychiatry of The Woodlands /ID# 250936 | The Woodlands | Texas |
United States | ClinPoint Trials /ID# 250942 | Waxahachie | Texas |
United States | CincyScience /ID# 250935 | West Chester | Ohio |
Lead Sponsor | Collaborator |
---|---|
AbbVie |
United States, Canada, Denmark, Hungary, Israel, Italy, Japan, Poland, Puerto Rico, Spain, Sweden, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants with Adverse Events (AEs) | AE, defined as any unfavorable medical event that is temporarily related to the use of the investigational product, which does not necessarily have a causal relationship with the investigational product. | Up to 56 Weeks | |
Primary | Percentage of Participants with Potentially Clinically Significant Lab Values | Percentage of participants with abnormal change in clinical laboratory test results like hematology, chemistry and urinalysis will be assessed. | Up to 52 Weeks | |
Primary | Percentage of Participants with Potentially Clinically Significant Clinical 12-lead Electrocardiogram (ECG) | 12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF). | Up to 52 Weeks | |
Primary | Percentage of Participants with Potentially Clinically Significant Vital Sign Parameters | Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed. | Up to 52 Weeks | |
Primary | Percentage of with Participants with Treatment-Emergent Suicidal Ideations with Intent, with or without a Plan (i.e., Type 4 or 5 on Columbia-Suicide Severity Rating Scale [C-SSRS]), or any Suicidal Behaviors | The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods [not plan] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). | Up to 52 Weeks | |
Primary | Percentage of Participants with Change in Menstrual Cycle (Female Participants Only) | Female participants who have entered menarche are to be asked for the date of the first and last day of their most recent menstrual period. | Up to 52 Weeks | |
Primary | Change from Baseline in Tanner Staging Score | Tanner's staging is used to assess growth and pubertal development. | Baseline (Week 0) through Week 52 | |
Primary | Change from Baseline in Behavior Rating Inventory of Executive Function, 2nd Edition (BRIEF 2) questionnaire | The BRIEF 2 is an 86-item questionnaire assessing executive function. It consists of 2 indexes, Behavioral Regulation and Metacognition, which are then used to calculate an overall composite score. Higher scores indicate more executive difficulties | Baseline (Week 0) through Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06047457 -
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
|
Phase 3 | |
Completed |
NCT02569853 -
DFN-11 Injection in Episodic Migraine With or Without Aura
|
Phase 3 | |
Completed |
NCT00719134 -
The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
|
Phase 4 | |
Completed |
NCT03700320 -
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
|
Phase 3 | |
Terminated |
NCT04936061 -
Transnasal Cooling for Migraine
|
N/A | |
Recruiting |
NCT05042037 -
Probiotics as Adjunctive Migraine Prophylaxis
|
N/A | |
Recruiting |
NCT05281770 -
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
|
||
Recruiting |
NCT04628429 -
CGRP Inhibition, Autonomic Function, and Migraine
|
||
Active, not recruiting |
NCT05028569 -
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
|
Phase 3 | |
Withdrawn |
NCT01257893 -
Aspirin Resistance in Women With Migraine
|
N/A | |
Recruiting |
NCT06051604 -
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
|
N/A | |
Completed |
NCT03132233 -
Energy for the Brain
|
N/A | |
Completed |
NCT03939312 -
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
|
Phase 3 | |
Completed |
NCT03927144 -
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
|
Phase 4 | |
Recruiting |
NCT06248671 -
Prophylactic Treatment With Atorvastatin for Episodic Migraine.
|
Phase 2 | |
Recruiting |
NCT05711394 -
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
|
Phase 3 | |
Recruiting |
NCT05449145 -
The Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic Migraine
|
N/A | |
Completed |
NCT04031781 -
The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis
|
N/A | |
Completed |
NCT05264129 -
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
|
Phase 4 | |
Completed |
NCT04740827 -
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
|
Phase 3 |